NunaBio

The company's core technology is a multi-patented, enzymatic process for manufacturing synthetic DNA, which avoids the use of hazardous chemicals. This allows for the synthesis of whole genes and DNA fragments of unprecedented length without the plasmids or primers that bottleneck traditional methods. NunaBio's platform offers a range of services including custom synthesis, contract research, and material supply. It provides an end-to-end solution covering DNA synthesis, assembly of long sequences, and amplification for production at scale. This technology serves a variety of applications in the life sciences market, such as gene therapy, T-cell engineering, vaccine development, diagnostics, and personalized medicine.

NunaBio operates as a contract research organization (CRO) and contract development and manufacturing organization (CDMO). Its business model focuses on providing custom solutions through synthesis contracts, research partnerships, and material supply agreements. The company has secured significant funding to expand its infrastructure and accelerate research and development, including a £1.9 million seed round in April 2023 and an additional £810,000 in September 2024 from investors like Northstar Ventures, Pioneer Group, Ascension Life Fund, and Martlet Capital.